| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg | |||
| Other Sizes |
| Targets |
Mecamylamine hydrochloride targets nicotinic acetylcholine receptors (nAChRs), where it acts as a noncompetitive and nonselective antagonist. It preferentially blocks nicotinic receptors at autonomic ganglia. Additionally, it has been shown to block histamine receptors in vascular tissue. Its ability to cross the blood-brain barrier allows it to selectively antagonize neuronal nAChRs in the central nervous system.
|
|---|---|
| ln Vitro |
Mecamylamine hydrochloride (0.5–9 μM, bath spray) enhances the frequency of fluorescence in 5-HT DRN (dorsal raphe nucleus) neurons that have been found [1]. Mecamylamine hydrochloride (0.5–9 μM, bath spray) increases glutamatergic input to 5-HT DRN neurons while decreasing GABAergic input [1]. In rabbit main rotary artery sections, mecamylamine hydrochloride (1 mM, 5 min) burns histamine and causes histamine-induced contraction [2]. Nicotine's neuroprotective properties are affected by mecamylamine hydrochloride (10 μM, 48 h) [3]. In HDMVEC, mecamylamine hydrochloride (1–100 nM, 30 minutes) reduces endothelial tube formation in a dose-dependent manner [4]. 3]
In vitro, mecamylamine enhances the firing of dorsal raphe 5-HT neurons by increasing glutamatergic input and reducing GABAergic input. As a noncompetitive inhibitor of nAChRs, it decreases channel open time and burst duration. It has also been studied for its effects on contractions induced by various agonists in isolated rabbit aorta preparations. |
| ln Vivo |
In a model of choroidal neovascularization (CNV), mecamylamine hydrochloride (subcutaneous pump, 50 mg/kg/day, 2 days) reduces CNV [4]. Mecamylamine hydrochloride (ip, 0.5–1 mg/kg) exhibits β2- and α7-subunit-dependent antidepressant-like effects in the tail suspension test (TST) and forced swim test (FST) in C57BL/6J mice [ 5].
In vivo, the hypotensive effect of mecamylamine is primarily attributed to a reduction in sympathetic tone, leading to vasodilation and reduced cardiac output. Its blood pressure-lowering effect is largely postural. Due to its ability to cross the blood-brain barrier, it acts both centrally and peripherally, which can result in a high incidence of peripheral side effects. |
| Enzyme Assay |
In vitro enzyme/receptor binding studies typically involve radioligand binding assays using membrane preparations from tissues or cells expressing nAChR subtypes. Competitive binding experiments with labeled ligands such as [3H]-epibatidine are performed to determine affinity and characterize its noncompetitive antagonism. Standard protocols involve incubating membranes with increasing concentrations of mecamylamine in the presence of a fixed concentration of radioligand, followed by filtration and scintillation counting.
|
| Cell Assay |
Western Blot Analysis[3]
Cell Types: SCG Neuronal Tested Concentrations: 10 μM Incubation Duration: 48 hrs (hours) Experimental Results: diminished nicotine-promoted increase in ERK1/2. In vitro cellular assays for mecamylamine often involve studying its effects on neuronal cell lines. For example, its modulation of dorsal raphe neuron firing is assessed by measuring glutamatergic and GABAergic input changes. Electrophysiological techniques, such as patch-clamp recordings, are used to evaluate its effects on nAChR channel function, including channel open time and burst duration. These assays help characterize its mechanism as a noncompetitive antagonist. |
| Animal Protocol |
Animal/Disease Models: Choroidal neovascularization (CNV) mouse model [1] Usage and
Doses: 50 mg/kg/day, 2 days of Route of Administration: A subcutaneouspump is implanted under the back skin, 200 μL, and the average pump speed is 0.5 μL/h. Experimental Results: In the absence of nicotine, the development of CNV at the site of Bruch's membrane rupture was inhibited. Animal/Disease Models: C57BL/6J mice [5] Doses: 0.5-1 mg/kg Route of Administration: intraperitoneal (ip) injection Experimental Results: No effect on β2 gene knockout mice and α7 gene knockout mice, but diminished wild-type littermates Mouse immobility time in FST. In vivo animal studies for mecamylamine are conducted in various models. For hypertension research, its effects on blood pressure are studied in animal models. For neuropsychiatric research, its antidepressant-like effects have been evaluated in wild-type and nAChR subunit knockout mice. Standard protocols involve administering the compound orally or via injection and measuring physiological or behavioral endpoints. |
| ADME/Pharmacokinetics |
Mecamylamine hydrochloride is an orally active compound that can cross the blood-brain barrier. It is rapidly absorbed and distributed throughout the body. The compound has a molecular weight of 203.75 and a molecular formula of C₁₁H₂₂ClN. Detailed pharmacokinetic parameters such as half-life and clearance are available in the literature for its clinical use as an antihypertensive agent.
|
| Toxicity/Toxicokinetics |
The primary toxicity of mecamylamine is related to its pharmacological effects as a ganglionic blocker, leading to significant side effects including orthostatic hypotension, constipation, dry mouth, and blurred vision. Its ability to cross the blood-brain barrier can result in central nervous system side effects such as sedation and tremor. Overdose can cause severe hypotension and respiratory depression. It is contraindicated in patients with coronary insufficiency and recent myocardial infarction.
|
| References |
|
| Additional Infomation |
Mecaramine hydrochloride is a monoterpenoid compound. See also: Mecaramine (with active moiety).
Mecamylamine hydrochloride was historically used as an antihypertensive agent but is now primarily a research tool for studying nAChR function. It is available as an analytical standard for research applications. Its role as a noncompetitive nAChR antagonist makes it valuable for studying nicotinic signaling in various neurological and psychiatric conditions. It is not currently approved for human therapeutic use in most jurisdictions. |
| Molecular Formula |
C11H22CLN
|
|---|---|
| Molecular Weight |
203.75
|
| Exact Mass |
203.144
|
| CAS # |
826-39-1
|
| Related CAS # |
Mecamylamine;60-40-2;Mecamylamine hydrochloride-13C4,15N
|
| PubChem CID |
13221
|
| Appearance |
White to off-white solid powder
|
| Boiling Point |
189.3ºC at 760 mmHg
|
| Melting Point |
>240ºC (dec.)
|
| Flash Point |
58.1ºC
|
| LogP |
3.613
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
1
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
13
|
| Complexity |
197
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
PKVZBNCYEICAQP-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C11H21N.ClH/c1-10(2)8-5-6-9(7-8)11(10,3)12-4;/h8-9,12H,5-7H2,1-4H3;1H
|
| Chemical Name |
N,2,3,3-tetramethylbicyclo[2.2.1]heptan-2-amine;hydrochloride
|
| Synonyms |
Mevasin; Mecamine hydrochloride Mecamylamine HCl; Inversine
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~100 mg/mL (~490.80 mM)
DMSO : ~31.25 mg/mL (~153.37 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (10.21 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (10.21 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (10.21 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.9080 mL | 24.5399 mL | 49.0798 mL | |
| 5 mM | 0.9816 mL | 4.9080 mL | 9.8160 mL | |
| 10 mM | 0.4908 mL | 2.4540 mL | 4.9080 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
